MTOR and myeloproliferative disorder: The combination of ruxolitinib with either an AKT inhibitor (MK-2206) or an mTOR inhibitor (rad001) synergistically suppressed the survival of MPN model cells and inhibited the neoplastic growth of primary MPN patient cells [85,86].